About IGC Pharma
IGC Pharma is a company based in Potomac (United States) founded in 2005. The company has 70 employees as of March 31, 2024. IGC Pharma offers products and services including IGC-AD1, CALMA, and TGR-63. IGC Pharma operates in a competitive market with competitors including Hyasynth Bio, GW Pharma, Hempsana, MIRA Pharmaceuticals and NEUROPATHIX, among others.
- Headquarter Potomac, United States
- Employees 70 as on 31 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Igc Pharma, Inc.
-
Annual Revenue
$1.27 M (USD)-5.5as on Mar 31, 2025
-
Net Profit
-$7.12 M (USD)45.22as on Mar 31, 2025
-
EBITDA
-$6.83 M (USD)25.47as on Mar 31, 2025
-
Latest Funding Round
$3 M (USD), Post-IPO
Mar 26, 2024
-
Investors
BRADBURY
& 1 more
-
Employee Count
70
as on Mar 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of IGC Pharma
IGC Pharma is a publicly listed company on the AMEX with ticker symbol IGC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of IGC Pharma
IGC Pharma offers a comprehensive portfolio of products and services, including IGC-AD1, CALMA, and TGR-63.
Treatment for agitation in Alzheimer's disease through clinical trials
Phase 2 trial program for Alzheimer's disease interventions
Potential therapy for neurological disorders like Alzheimer's
People of IGC Pharma
Unlock access to complete
Funding Insights of IGC Pharma
Investors in IGC Pharma
IGC Pharma has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include BRADBURY and Bradbury.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
It serves as a bradbury.
|
Locked | Locked | Locked | |
|
Bradbury is engaged in providing financial and investment services.
|
Locked | Locked | Locked |
Investor details for IGC Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by IGC Pharma
Investment portfolio details for IGC Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - IGC Pharma
Detailed financials for IGC Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Igc Pharma Comparisons
Peer comparison for IGC Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of IGC Pharma
IGC Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Hyasynth Bio, GW Pharma, Hempsana, MIRA Pharmaceuticals and NEUROPATHIX, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of cannabinoid products intended to treat neurological disorders
|
|
| Locked | Locked | Locked |
Developer of cannabinoid medicines for MS spasticity, cancer pain and childhood epilepsy
|
|
| Locked | Locked | Locked |
CBD oil processing solutions from hemp plants are provided.
|
|
| Locked | Locked | Locked |
Cannabinoid-based therapeutics for chronic pain and anxiety are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics targeting inflammation, neurodegeneration, oxidative stress, and neuropathic pain
|
Detailed competitors of IGC Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Igc Pharma
Complete news archive for IGC Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IGC Pharma
IGC Pharma was founded in 2005 and raised its 1st funding round 18 years after it was founded.
IGC Pharma is headquartered in Potomac, United States. It is registered at Potomac, Maryland, United States.
Ram Mukunda is the current CEO of IGC Pharma.
As of Mar 31, 2024, the latest employee count at IGC Pharma is 70.
Annual revenue of IGC Pharma is $1.27M as on Mar 31, 2025.
Founded in 2005 and headquartered in Potomac, United States, pharmaceutical therapies for neurological disorders, including Alzheimers disease, are developed by IGC Pharma. Focus is placed on addressing agitation and disease progression through drug candidates at various development stages. Artificial intelligence is utilized to optimize clinical trials and support early detection efforts within the biotechnology sector.
IGC Pharma's top competitors include MIRA Pharmaceuticals, GW Pharma and Hyasynth Bio.
IGC Pharma offers IGC-AD1, CALMA, and TGR-63.
Yes, IGC Pharma is publicly traded on AMEX under the ticker symbol IGC.
The ticker symbol of IGC Pharma is IGC on AMEX.